Continuing to build on two decades of progress
In the last 20 years we've invested over £37 million into groundbreaking research. Today, we know more about prostate cancer than we could have imagined even a few years ago. We’re getting to grips with how it evolves, what it looks like at a molecular level, and how it can vary between one man and another.
There are new life-prolonging treatments for advanced disease, and health authorities at last see the importance of consistent, quality care for men living with and after prostate cancer.
But there’s still so much more we need to learn, and we’re not going to stop until we’ve got the answers to all our questions. That’s why we’re investing heavily in research, focusing on three areas:
- Better diagnosis
We’ll fund research that will pick up on aggressive prostate cancer sooner, predict and manage the impact it will have, and reduce today’s number of biopsies and unnecessary treatments for cancers that are harmless.
- Better treatments
We’ll invest in putting effective treatments, with fewer side effects, into the hands of the men who need them, wherever they live in the UK.
- Better prevention
The first step in stopping prostate cancer is to understand what starts it and what makes cancer cells tick. The second is blocking its return following primary treatment. For us, both are a priority.